HTG Molecular Diagnostics, Inc. (Formerly Known as High Throughput Genomics, Inc.) and Sanofi US Collaborate to Identify B-cell Malignancy Biomarkers
TUCSON, AZ--(Marketwire - March 30, 2012) -
Highlighted Links |
HTG Molecular Diagnostics |
"We are pleased to be a partner with Sanofi in answering the need for personalized cancer treatments. qNPA offers options in diagnostics testing of FFPE tissues not available in other commercial technologies," said TJ Johnson, CEO of HTG Molecular Diagnostics.
ABOUT HTG MOLECULAR DIAGNOSTICS:
HTG Molecular Diagnostics is a privately-held, Tucson-based company providing products for gene expression profiling, miRNA, siRNA and mRNA measurement for clinical research, companion diagnostic and prognostic applications in oncology. The company's qNPA molecular technology platform is well-suited for reliably detecting changes in gene expression levels especially from formalin-fixed, paraffin-embedded (FFPE) tissue. Additional information is available at www.htgmolecular.com.
Media Contact:
Kimberly Schmitz
Spur Public Relations.
520.247.5778
Email Contact
Company Contact:
TJ Johnson
Chief Executive Officer
HTG Molecular Diagnostics
520.547.2827
Email Contact